The effect of cinacalcet on calcific uremic arteriolopathy events in patients receiving hemodialysis: The EVOLVE trial

Clinical Journal of the American Society of Nephrology

Volumn 10, Issue 5, 2015, Pages 800-807

  Floege, Jürgen ^a   Kubo, Yumi ^b   Floege, Anna ^a   Chertow, Glenn M ^c   Parfrey, Patrick S ^d  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b AMGEN INC   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; CINACALCET; ERYTHROPOIETIN; PHOSPHATE BINDING AGENT; PLACEBO; WARFARIN; CALCIMIMETIC AGENT; PARATHYROID HORMONE; VITAMIN K GROUP;

ADULT; ARTICLE; BODY MASS; BONE DISEASE; CALCINOSIS; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HEMODIALYSIS; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PATIENT HISTORY OF PARATHYROIDECTOMY; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; TOBACCO USE; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD PRESSURE; CALCIPHYLAXIS; CLINICAL TRIAL; COMPLICATION; DYSLIPIDEMIAS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; MULTICENTER STUDY; PARATHYROIDECTOMY; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE;

ADULT; AGED; BLOOD PRESSURE; BODY MASS INDEX; CALCIMIMETIC AGENTS; CALCIPHYLAXIS; CINACALCET HYDROCHLORIDE; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; PARATHYROIDECTOMY; RENAL DIALYSIS; RISK FACTORS; SEX FACTORS; VITAMIN K;

EID: 84929224099     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.10221014     Document Type: Article

References (21)

1. Brandenburg VM, Sinha S, Specht P, Ketteler M: Calcific uraemic arteriolopathy: A rare disease with a potentially high impact on chronic kidney disease-mineral and bone disorder. Pediatr Nephrol 29: 2289–2298, 2014
2. Coates T, Kirkland GS, Dymock RB, Murphy BF, Brealey JK, Mathew TH, Disney AP: Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis 32: 384–391, 1998
3. Fine A, Zacharias J: Calciphylaxis is usually non-ulcerating: Risk factors, outcome and therapy. Kidney Int 61: 2210–2217, 2002
4. Mazhar AR, Johnson RJ, Gillen D, Stivelman JC, Ryan MJ, Davis CL, Stehman-Breen CO: Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 60: 324–332, 2001
5. Weenig RH, Sewell LD, Davis MD, McCarthy JT, Pittelkow MR: Calciphylaxis: Natural history, risk factor analysis, and outcome. J Am Acad Dermatol 56: 569–579, 2007
6. Nigwekar SU, Wolf M, Sterns RH, Hix JK: Calciphylaxis from nonuremic causes: A systematic review. Clin JAmSoc Nephrol 3: 1139–1143, 2008
7. Brandenburg VM, Cozzolino M, Ketteler M: Calciphylaxis: A still unmet challenge. J Nephrol 24: 142–148, 2011
8. Don BR, Chin AI: A strategy for the treatment of calcific uremic arteriolopathy (calciphylaxis) employing a combination of therapies. Clin Nephrol 59: 463–470, 2003
9. Hayden MR, Goldsmith D, Sowers JR, Khanna R: Calciphylaxis: Calcific uremic arteriolopathy and the emerging role of sodium thiosulfate. Int Urol Nephrol 40: 443–451, 2008
10. Kramann R, Brandenburg VM, Schurgers LJ, Ketteler M, Westphal S, Leisten I, Bovi M, Jahnen-Dechent W, Knüchel R, Floege J, Schneider RK: Novel insights into osteogenesis and matrix remodelling associated with calcific uraemic arteriolopathy. Nephrol Dial Transplant 28: 856–868, 2013
11. Hayashi M, Takamatsu I, Kanno Y, Yoshida T, Abe T, Sato Y; Japanese Calciphylaxis Study Group: A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant 27: 1580–1584, 2012
12. Nigwekar SU, Bhan I, Turchin A, Skentzos SC, Hajhosseiny R, Steele D, Nazarian RM, Wenger J, Parikh S, Karumanchi A, Thadhani R: Statin use and calcific uremic arteriolopathy: A matched case-control study. Am J Nephrol 37: 325–332, 2013
13. Mawad HW, Sawaya BP, Sarin R, Malluche HH: Calcific uremic arteriolopathy in association with low turnover uremic bone disease. Clin Nephrol 52: 160–166, 1999
14. Katikaneni M, Lwin L, Villanueva H, Yoo J: Calciphylaxis and subtotal parathyroidectomy: a double-edged sword. Hemodial Int 17[Suppl 1]: S33–S36, 2013
15. Chertow GM, Correa-Rotter R, Block GA, Drueke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Wheeler DC, Parfrey PS: Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. Nephrol Dial Transplant 27: 2872–2879, 2012
16. Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS, Parfrey PS: Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367: 2482–2494, 2012
17. Chertow GM, Pupim LB, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, London GM, Mahaffey KW, Moe SM, Wheeler DC, Albizem M, Olson K, Klassen P, Parfrey P: Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): Rationale and design overview. Clin J AmSoc Nephrol 2: 898–905, 2007
18. Parfrey PS, Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Dehmel B, Trotman ML, Modafferi DM, Goodman WG: The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial. J Clin Endocrinol Metab 98: 4834–4844, 2013
19. Angelis M, Wong LL, Myers SA, Wong LM: Calciphylaxis in patients on hemodialysis: A prevalence study. Surgery 122: 1083–1089, discussion 1089–1090, 1997
20. Ketteler M, Wanner C, Metzger T, Bongartz P, Westenfeld R, Gladziwa U, Schurgers LJ, Vermeer C, Jahnen-Dechent W, Floege J: Deficiencies of calcium-regulatory proteins in dialysis patients: A novel concept of cardiovascular calcification in uremia. Kidney Int Suppl (84 Suppl): S84–S87, 2003
21. Krüger T, Floege J: Vitamin K antagonists: Beyond bleeding. Semin Dial 27: 37–41, 2014